Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$3.18 +2.9%	$2.56	$1.47 ▼ $17.31	$75.48M	2.99	60,490 shs	45,936 shs
IGMS IGM Biosciences	$1.27	$1.28	$0.92 ▼ $22.50	$76.57M	0.6	480,746 shs	N/A
IXHL Incannex Healthcare	$0.62 -2.2%	$0.51	$0.08 ▼ $3.12	$19.40M	7.66	134.11 million shs	31.21 million shs
KLRS Kalaris Therapeutics	$4.57 +14.3%	$2.73	$2.14 ▼ $24.15	$76.31M	0.37	79,202 shs	10.84 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	+2.91%	-2.75%	+5.65%	+62.24%	-71.12%
IGMS IGM Biosciences	0.00%	0.00%	-2.31%	+2.42%	-87.12%
IXHL Incannex Healthcare	-2.19%	-6.91%	+40.32%	+248.60%	-63.93%
KLRS Kalaris Therapeutics	+14.25%	+48.38%	+77.13%	+46.95%	+456,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARTV Artiva Biotherapeutics	3.2427 of 5 stars	3.5	0.0	0.0	3.1	2.5	1.3
IGMS IGM Biosciences	4.2261 of 5 stars	3.0	3.0	4.6	1.1	3.3	1.3
IXHL Incannex Healthcare	0.5136 of 5 stars	0.0	4.0	0.0	1.9	0.8	0.0
KLRS Kalaris Therapeutics	1.2421 of 5 stars	1.5	0.0	0.0	4.1	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTV Artiva Biotherapeutics	3.00	Buy	$17.00	434.59% Upside
IGMS IGM Biosciences	1.90	Reduce	$5.50	333.07% Upside
IXHL Incannex Healthcare	0.00	N/A	N/A	N/A
KLRS Kalaris Therapeutics	3.00	Buy	$3.00	-34.35% Downside

Current Analyst Ratings Breakdown

Latest IXHL, ARTV, IGMS, and KLRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2025	KLRS Kalaris Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy
7/23/2025	KLRS Kalaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral	$3.00
7/23/2025	KLRS Kalaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$3.00
6/11/2025	ARTV Artiva Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$12.00

(Data available from 9/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	$6.10 per share	N/A
IGMS IGM Biosciences	$145.05M	0.53	N/A	N/A	$1.67 per share	0.76
IXHL Incannex Healthcare	$10K	1,836.43	N/A	N/A	$0.18 per share	3.47
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	$2.84 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTV Artiva Biotherapeutics	-$65.37M	N/A	0.00	N/A	N/A	N/A	-42.60%	-37.76%	11/11/2025 (Estimated)
IGMS IGM Biosciences	-$195.79M	-$0.90	N/A	N/A	N/A	-36.81%	-93.35%	-24.15%	11/14/2025 (Estimated)
IXHL Incannex Healthcare	-$18.46M	-$1.21	N/A	∞	N/A	N/A	-342.92%	-148.64%	9/29/2025 (Estimated)
KLRS Kalaris Therapeutics	-$58.77M	N/A	0.00	∞	N/A	N/A	-81.02%	-65.15%	N/A

Latest IXHL, ARTV, IGMS, and KLRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/29/2025	Q4 2025	IXHL Incannex Healthcare	-$0.29	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	KLRS Kalaris Therapeutics	-$0.51	-$0.61	-$0.10	-$0.61	N/A	N/A
8/6/2025	Q2 2025	ARTV Artiva Biotherapeutics	-$0.84	-$0.87	-$0.03	-$0.87	N/A	N/A
7/31/2025	Q2 2025	IGMS IGM Biosciences	-$0.30	$1.58	+$1.88	$1.58	$3.20 million	$143.62 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
IGMS IGM Biosciences	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTV Artiva Biotherapeutics	N/A	13.84	13.84
IGMS IGM Biosciences	N/A	17.66	17.66
IXHL Incannex Healthcare	N/A	2.12	2.12
KLRS Kalaris Therapeutics	N/A	11.98	11.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARTV Artiva Biotherapeutics	N/A
IGMS IGM Biosciences	42.79%
IXHL Incannex Healthcare	0.43%
KLRS Kalaris Therapeutics	66.05%

Insider Ownership

Company	Insider Ownership
ARTV Artiva Biotherapeutics	21.40%
IGMS IGM Biosciences	57.00%
IXHL Incannex Healthcare	15.49%
KLRS Kalaris Therapeutics	74.99%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTV Artiva Biotherapeutics	81	24.43 million	19.20 million	N/A
IGMS IGM Biosciences	190	60.29 million	25.93 million	Optionable
IXHL Incannex Healthcare	3	29.43 million	24.88 million	Not Optionable
KLRS Kalaris Therapeutics	110	18.70 million	4.68 million	N/A

IXHL, ARTV, IGMS, and KLRS Headlines

Recent News About These Companies

Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know

September 1 at 1:01 PM | zacks.com

Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 13, 2025 | globenewswire.com

Bernstein Liebhard LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of AlloVir, Inc. Securities

June 5, 2025 | globenewswire.com

Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference

June 2, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL, ARTV, IGMS, and KLRS Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

$3.18 +0.09 (+2.91%)

Closing price 09/3/2025 04:00 PM Eastern

Extended Trading

$3.16 -0.02 (-0.63%)

As of 09/3/2025 07:57 PM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

IGM Biosciences NASDAQ:IGMS

$1.27 0.00 (0.00%)

As of 08/14/2025

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Incannex Healthcare NASDAQ:IXHL

$0.62 -0.01 (-2.19%)

Closing price 09/3/2025 04:00 PM Eastern

Extended Trading

$0.62 0.00 (-0.48%)

As of 09/3/2025 07:59 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

Kalaris Therapeutics NASDAQ:KLRS

$4.57 +0.57 (+14.25%)

As of 09/3/2025 04:00 PM Eastern

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time